Last reviewed · How we verify
Aceclidine+Brimonidine combination ophthalmic solution
This combination stimulates muscarinic receptors (via aceclidine) and alpha-2 adrenergic receptors (via brimonidine) to increase aqueous humor outflow and reduce intraocular pressure in the eye.
This combination stimulates muscarinic receptors (via aceclidine) and alpha-2 adrenergic receptors (via brimonidine) to increase aqueous humor outflow and reduce intraocular pressure in the eye. Used for Glaucoma or ocular hypertension (intraocular pressure reduction).
At a glance
| Generic name | Aceclidine+Brimonidine combination ophthalmic solution |
|---|---|
| Also known as | LNZ101, Brimonidine and Aceclidine |
| Sponsor | LENZ Therapeutics, Inc |
| Drug class | Muscarinic agonist + alpha-2 adrenergic agonist combination |
| Target | Muscarinic acetylcholine receptors; alpha-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Aceclidine is a direct-acting muscarinic agonist that enhances trabecular meshwork outflow facility. Brimonidine is an alpha-2 adrenergic agonist that reduces aqueous humor production and increases uveoscleral outflow. Together, these complementary mechanisms provide dual pathways for intraocular pressure reduction in glaucoma and ocular hypertension.
Approved indications
- Glaucoma or ocular hypertension (intraocular pressure reduction)
Common side effects
- Ocular hyperemia
- Ocular irritation
- Blurred vision
- Allergic conjunctivitis
- Dry eye
Key clinical trials
- Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia (PHASE3)
- Phase 3 Safety Study for the Treatment of Presbyopia Subjects (PHASE3)
- Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia (PHASE2)
- Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia (PHASE2)
- Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: